Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18252
Country/Region: Botswana
Year: 2017
Main Partner: Government of Botswana
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,282,174 Additional Pipeline Funding: $210,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $163,598
Care: TB/HIV (HVTB) $57,100
Care: Pediatric Care and Support (PDCS) $34,813
Laboratory Infrastructure (HLAB) $15,000
Testing: HIV Testing and Counseling (HVCT) $88,276
Sexual Prevention: Other Sexual Prevention (HVOP) $100,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,200
Treatment: ARV Drugs (HTXD) $56,824
Treatment: Adult Treatment (HTXS) $730,550
Treatment: Pediatric Treatment (PDTX) $34,813
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
PMTCT_ART Already on ART at beginning of current pregnancy 2018 6
PMTCT_ART New on ART 2018 4
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 10
TX_CURR Aggregated Age/Sex: 15+ Female 2018 99
TX_CURR Aggregated Age/Sex: 15+ Male 2018 231
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 330
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 330
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 330
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 12
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 28
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 40
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 40
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 313
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 323
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 99
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 231
TX_PVLS Numerator: Indication: Routine 2018 323
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 94
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 219
TX_PVLS_den Denominator: Indication: Routine 2018 313
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 7
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 23
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 23
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 25
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 18
VMMC_CIRC By Age: 10-14 2018 300
VMMC_CIRC By Age: 15-19 2018 600
VMMC_CIRC By Age: 20-24 2018 1,200
VMMC_CIRC By Age: 25-29 2018 2,100
VMMC_CIRC By Age: 30-49 2018 1,200
VMMC_CIRC By Age: 50+ 2018 600
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 6,000
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 6,000
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 6,000
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 2,700